Sign in with your email address username.


[Correspondence] Partial breast irradiation and the GEC-ESTRO trial

The results of the GEC-ESTRO phase 3 trial1 add to the growing body of level I evidence supporting accelerated partial breast irradiation (APBI), as an equal alternative to whole breast irradiation (WBI) in selected patients with early stage breast cancer treated with breast-conserving therapy.2–4 With a median follow-up of 6·6 years, the 5-year actuarial rates of local recurrence, disease-free survival, and cause-specific survival were not significantly different.1 Just as important, all measures of acute and chronic toxic effects showed no differences between approaches, with only a slight advantage noted with APBI for breast pain and skin side-effects of grade 2–3.